Twin Tree Management LP Cuts Stock Holdings in Illumina, Inc. $ILMN

Twin Tree Management LP reduced its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 68.2% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,504 shares of the life sciences company’s stock after selling 33,196 shares during the period. Twin Tree Management LP’s holdings in Illumina were worth $1,230,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Moors & Cabot Inc. increased its stake in Illumina by 2.5% during the 1st quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company’s stock worth $465,000 after buying an additional 145 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. increased its stake in Illumina by 3.0% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company’s stock worth $445,000 after buying an additional 164 shares in the last quarter. Probity Advisors Inc. increased its stake in Illumina by 12.2% during the 4th quarter. Probity Advisors Inc. now owns 2,054 shares of the life sciences company’s stock worth $274,000 after buying an additional 224 shares in the last quarter. Xponance Inc. increased its stake in Illumina by 1.0% during the 1st quarter. Xponance Inc. now owns 26,762 shares of the life sciences company’s stock worth $2,123,000 after buying an additional 264 shares in the last quarter. Finally, Rakuten Securities Inc. increased its stake in Illumina by 290.3% during the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock worth $29,000 after buying an additional 270 shares in the last quarter. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on ILMN. Robert W. Baird boosted their price objective on Illumina from $84.00 to $105.00 and gave the stock a “neutral” rating in a research note on Monday, July 28th. Royal Bank Of Canada boosted their target price on Illumina from $118.00 to $126.00 and gave the stock an “outperform” rating in a report on Friday, August 1st. Daiwa America cut Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 12th. JPMorgan Chase & Co. lowered their target price on Illumina from $120.00 to $85.00 and set a “neutral” rating on the stock in a report on Friday, May 9th. Finally, Scotiabank cut Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 target price on the stock. in a report on Friday, July 11th. Six investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Illumina presently has a consensus rating of “Hold” and a consensus price target of $123.17.

Illumina Trading Up 0.8%

ILMN opened at $99.96 on Monday. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66. The stock has a market capitalization of $15.36 billion, a PE ratio of 12.65, a P/E/G ratio of 2.25 and a beta of 1.43. The business’s 50 day moving average price is $99.10 and its 200 day moving average price is $88.47. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm had revenue of $1.06 billion for the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the prior year, the firm posted $0.36 earnings per share. The firm’s quarterly revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.